In a proof-of-principle study in mice, scientists at Johns Hopkins Medicine report the creation of a specialized gel that acts like a lymph node to successfully activate and multiply cancer-fighting immune system T-cells. The work puts scientists a step closer, they say, to injecting such artificial lymph nodes into people and sparking T-cells to fight disease.
In the past few years, a wave of discoveries has advanced new techniques to use T-cells — a type of white blood cell — in cancer treatment. To be successful, the cells must be primed, or taught, to spot and react to molecular flags that dot the surfaces of cancer cells. The job of educating T-cells this way typically happens in lymph nodes, small, bean-shaped glands found all over the body that house T-cells. But in patients with cancer and immune system disorders, that learning process is faulty, or doesn’t happen.
To address such defects, current T-cell booster therapy requires physicians to remove T-cells from the blood of a patient with cancer and inject the cells back into the patient after either genetically engineering or activating the cells in a laboratory so they recognize cancer-linked molecular flags.
One such treatment, called CAR-T therapy, is costly and available only at specialized centers with laboratories capable of the complicated task of engineering T-cells. In addition, it generally takes about six to eight weeks to culture the T-cells in laboratories and, once reintroduced into the body, the cells don’t last long in the patient’s body, so the effects of the treatment can be short-lived.
The new work, reported April 10 in the journal Advanced Materials, is a bid by Johns Hopkins scientists to find a more efficient way of engineering T-cells.
“We believe that a T-cell’s environment is very important. Biology doesn’t occur on plastic dishes; it happens in tissues,” says John Hickey, a Ph.D. candidate in biomedical engineering at the Johns Hopkins University School of Medicine and first author of the study report.
To make the engineered T-cells’ environment more biologically realistic, Hickey — working with his mentors Hai-Quan Mao, Ph.D., associate director of the Johns Hopkins Institute for NanoBioTechnology and Jonathan Schneck, M.D., Ph.D., professor of pathology, medicine and oncology at the Johns Hopkins University School of Medicine — tried using a jelly-like polymer, or hydrogel, as a platform for the T-cells. On the hydrogel, the scientists added two types of signals that stimulate and “teach” T-cells to hone in on foreign targets to destroy.
In their experiments, T-cells activated on hydrogels produced 50 percent more molecules called cytokines, a marker of activation, than T-cells kept on plastic culture dishes.
Because hydrogels can be made to order, the Johns Hopkins scientists created and tested a range of hydrogels, from the very soft feel of a single cell to the more rigid quality of a cell-packed lymph node.
“One of the surprising findings was that T-cells prefer a very soft environment, similar to interactions with individual cells, as opposed to a densely packed tissue,” says Schneck.
More than 80 percent of T-cells on the soft surface multiplied themselves, compared with none of the T-cells on the most firm type of hydrogel.
When the Johns Hopkins team put T-cells onto a soft hydrogel, they found that the T-cells multiplied from just a few cells to about 150,000 cells — plenty to use for cancer therapy — within seven days. By contrast, when the scientists used other conventional methods to stimulate and expand T-cells, they were able to culture only 20,000 cells within seven days.
In the next set of experiments, the scientists injected the T-cells engineered in either the soft hydrogels or the plastic culture dishes into mice implanted with melanoma, a lethal form of skin cancer. Tumors in mice with T-cells cultured on hydrogels remained stable in size, and some of the mice survived beyond 40 days. By contrast, tumors grew in most of the mice injected with T-cells cultured in plastic dishes, and none of these mice lived beyond 30 days.
“As we perfect the hydrogel and replicate the essential feature of the natural environment, including chemical growth factors that attract cancer-fighting T-cells and other signals, we will ultimately be able to design artificial lymph nodes for regenerative immunology-based therapy,” says Schneck, a member of the Johns Hopkins Kimmel Cancer Center.
The Latest on: Artificial lymph nodes
via Google News
The Latest on: Artificial lymph nodes
- Lightpoint Medical Receives CE Mark for World's First Approved Robotic Gamma Probeon January 19, 2021 at 10:40 pm
CHESHAM, England, Jan. 20, 2021 /PRNewswire/ -- Lightpoint Medical, a medical device company developing miniaturized surgical tools for advanced intra-operative cancer detection, announced today ...
- Inorganic Nanoparticles for Predictive Oncology of Breast Canceron January 17, 2021 at 4:00 pm
Medicine could employ such systems to improve the tissue compatibility of implants, or to create scaffolds for tissue regeneration, or perhaps even to build artificial organs, for example ...
- Nanoengineering Approaches to the Design of Artificial Antigen-presenting Cellson January 16, 2021 at 4:00 pm
Acellular artificial antigen-presenting cells (aAPCs ... with improved in vivo performance due to easy access to draining lymph nodes, and suitability for intravenous injection.
- Deep learning sharpens near-infrared images for cancer diagnosticson January 15, 2021 at 8:03 am
Next, the team used the trained neural network to transform wide-field NIR-IIa fluorescence images of lymph nodes in a mouse injected with ... which would be an excellent application of artificial ...
- FDA Conditionally Approves First Oral Tablet to Treat Lymphoma in Dogson January 12, 2021 at 3:23 am
a type of cancer of the lymph nodes and lymphatic system. Laverdia-CA1 works to prevent certain proteins from leaving the nucleus of cancer cells, thereby allowing these proteins to control the ...
- The Chartis Group Repositions Brand Ahead of Healthcare's Next Chapteron January 11, 2021 at 12:10 pm
The Chartis Group, a leading healthcare advisory and analytics firm, announced today the launch of Next Intelligence, reflecting its position in the healthcare industry at a time of significant change ...
- Acute Lymphocytic Leukemia Therapeutics Market Size, Share, Growth, Trends, Analysis and Forecast - 2025on December 18, 2020 at 4:18 am
ALL occurs in the bone marrow and rapidly invades other parts of the body, including the liver, spleen, lymph nodes, liver ... Forecast 2019-2025 Global Edge Artificial Intelligence (AI) Software ...
- Kiromic Announces Submission of Two IND Applications for PD1 Gamma-delta CAR - T cell Therapy with the FDAon December 17, 2020 at 9:46 am
HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma (“the Company”) (NASDAQ: KRBP), a target discovery and gene-editing company utilizing artificial ... or para-aortic lymph nodes can be involved.
- Blood canceron August 16, 2020 at 12:01 pm
It is a network of vessels comprising your lymph nodes, spleen ... that cut down your breast cancer risk significantly. Artificial Intelligence can help detect blood cancer: Study Researchers ...
- 2020 Prostate Cancer - Matthew Rettig (Presentation - Artificial Intelligence in Prostate Cancer) - 1982on February 19, 2020 at 4:00 pm
Thank you for the invitation to speak today. And I'll be talking about the application of artificial intelligence or AI to PSMA PET-CT imaging in prostate cancer. So here are my disclosures, and ...
via Bing News